European Journal of Clinical Pharmacology

Ulukol, B.; Köksal, Y.; Cin, S.

doi: 10.1007/s002280050681pmid: 10638387

Objective: The aim of this study was to assess and compare the efficacy and tolerability of paracetamol, ibuprofen and nimesulide in children with upper respiratory tract infections (URTIs).

Widerlöv, E.; Jostell, K. -G.; Claesson, L.; Odlind, B.; Keisu, M.; Freyschuss, U.

doi: 10.1007/s002280050682pmid: 10638388

Objective: To study the influence of food intake on electrocardiogram (ECG) variables (heart rate, QT-, QTc-, PR-intervals, QRS-time) and morphological alterations of the T-waves in 12 healthy male volunteers.

Mueck, A. O.; Seeger, H.; Lippert, T. H.

doi: 10.1007/s002280050683pmid: 10638389

Objective: Fluvastatin is an agent of a new lipid lowering drug class, the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, which seems to elicit direct effects on the vasculature.

Marzo, A.; Ceppi Monti, N.; Vuksic, D.

doi: 10.1007/s002280050684pmid: 10638390

Objective: The extrapolated area under the concentration–time curve (AUC0–∞) for any drug is considered by operating guidelines as the primary parameter related to the extent of absorption in single-dose bioavailability and bioequivalence trials. Not more than 20% should be added to the experimental AUC (AUC0–t) in the extrapolating procedure. However, in certain specific cases, it is problematic and, in other cases, impossible to respect the above requirement. It was intended to demonstrate that truncated AUC or AUC0–t would be used in bioequivalence trials when the AUC cannot be extrapolated.

Burnier, M.; Fricker, A. F.; Hayoz, D.; Nussberger, J.; Brunner, H. R.

doi: 10.1007/s002280050685pmid: 10638391

Objective: The pharmacokinetic and pharmacodynamic properties of YM087, (4′-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)-carbonyl]-2-phenylbenzanilide monohydrochloride), a new orally active, dual V1/V2 receptor antagonist were characterised in healthy normotensive subjects.

Guthrie, S. K.; Zubieta, J. -K.; Ohl, L.; Koeppe, R. A.; Minoshima, S.; Domino, E. F.

doi: 10.1007/s002280050686pmid: 10638392

Background and objectives: Arterial (A) and venous (V) plasma nicotine and cotinine concentrations were measured after nasal nicotine spray in tobacco smokers of both genders. The hypothesis for this research was that a greater A/V difference in plasma nicotine would be present in males than females because males have greater skeletal muscle mass to bind nicotine.

Ahola, T.; Fellman, V.; Laaksonen, R.; Laitila, J.; Lapatto, R.; Neuvonen, P. J.; Raivio, K. O.

doi: 10.1007/s002280050687pmid: 10638393

Background: Reactive oxygen species have been considered to play a role in several clinical complications in pre-term infants. The aim of this study was to determine the pharmacokinetics of intravenous N-acetylcysteine in pre-term neonates. This information is needed to evaluate the use of N-acetylcysteine as an antioxidant in this patient group.

Suarez-Kurtz, G.; Vicente, F. L.; Ponte, C. G.; Buy, V. L. M.; Struchiner, C. J.

doi: 10.1007/s002280050688pmid: 10638394

Objective: Develop and validate limited-sampling strategy (LSS) models for estimating the area under the plasma concentration versus time curve (AUC) of amlodipine, using data from a bioequivalence study.

Vandel, P.; Haffen, E.; Vandel, S.; Bonin, B.; Nezelof, S.; Sechter, D.; Broly, F.; Bizouard, P.; Dalery, J.

doi: 10.1007/s002280050689pmid: 10638395

Objective: Among Caucasians, a lack of cytochrome P 450 enzyme CYP2D6 is observed in 5–10% of individuals, named poor metabolizers (PMs). A consequence may be an impaired metabolism of many drugs such as most of the psychotropic drugs with an increased risk of drug side effects. This enzyme is also involved in the metabolism of endogenous compounds, including neurotransmitters such as dopamine and dopamine-related neurotransmitters which play a role in the mechanism of action of extrapyramidal drug side effects. The present study investigates whether patients who have developed and those who have not developed extrapyramidal drug side effects differ in their CYP2D6 genotypes and phenotypes.

Nägele, H.; Petersen, B.; Bonacker, U.; Rödiger, W.

doi: 10.1007/s002280050690pmid: 10638396

Objective: We detected markedly decreased cyclosporin blood levels in a heart-transplanted patient after the gastrointestinal lipase inhibitor orlistat was accidentally added to the treatment program to control for his obesity. Therefore, we determined cyclosporin plasma concentration time kinetics with and without orlistat reexposition in this patient.